CorMedix Stock Soars 17.79% on Strong Q1 Earnings
1min read On April 8, 2025, CorMedix's stock surged by 17.79% in pre-market trading, reflecting strong investor confidence in the company's recent financial performance and strategic initiatives.
CorMedix reported impressive preliminary Q1 2025 results, with unaudited net revenue of $39.0 million and expected adjusted EBITDA exceeding $22.5 million. This financial performance underscores the company's robust commercial execution and operational efficiency. The strong revenue generation and impressive EBITDA margin highlight CorMedix's ability to effectively manage its operations and drive growth.
The company has raised its H1 2025 net sales guidance to $62-70 million, driven by larger-than-anticipated orders in late March and improved visibility into customer inventory levels. While Q2 2025 sales are expected to be lower than Q1 due to shipment timing, patient utilization is forecast to grow throughout 2025, with H2 shipments projected to exceed H1. This indicates an accelerating growth trajectory and validates the product's value proposition and commercial strategy.
CorMedix's cash position stands at $77.5 million as of March 31, 2025, providing significant liquidity to fund ongoing operations and planned clinical development. The company plans to begin patient enrollment for DefenCath's Phase 3 study in Total Parenteral Nutrition (TPN) patients in late April. If approved, DefenCath's peak annual sales potential in this indication is estimated at $150-200 million, with a total addressable market of $500-750 million. This expansion into the TPN market represents a significant growth catalyst for cormedix, further broadening DefenCath's clinical utility and market reach.
